Biopharmaceutical company Navidea Biopharmaceuticals, Inc. is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics, operating in two segments: Diagnostic Substances and Therapeutic Development Programs. The company has developed the Manocept platform to target the CD206 mannose receptor for a range of diagnostic modalities, including PET, gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages and immune-and inflammation-involved diseases. Navidea's NAV3-31 has completed Phase IIb clinical trials for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis, while NAV3-35 is in a Phase IIb clinical trial for RA imaging, and NAV3-33 is in a Phase III clinical trial for RA. The company is also developing Tc99m tilmanocept for applications in cardiovascular disease, Kaposi's sarcoma, tuberculosis, and other immunotherapeutic areas. Navidea Biopharmaceuticals, Inc. was formerly known as Neoprobe Corporation and was incorporated in 1983, with headquarters in Dublin, Ohio.